Amerikanische Gesellschaft für Hirudotherapie

Clinical and Genetic Risk Factors for Acute Incident Venous Thromboembolism in Ambulatory Patients With COVID-19.

Research article published in JAMA internal medicine (2022)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportKlinische StudienGenomik & ProteomikXie J et al. · JAMA internal medicine, 2022

Abstract

IMPORTANCE: The risk of venous thromboembolism (VTE) in ambulatory COVID-19 is controversial. In addition, the association of vaccination with COVID-19-related VTE and relevant clinical and genetic risk factors remain to be elucidated. OBJECTIVE: To quantify the association between ambulatory COVID-19 and short-term risk of VTE, study the potential protective role of vaccination, and investigate clinical and genetic risk factors for post-COVID-19 VTE. DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study of patients with COVID-19 from UK Biobank included participants with SARS-CoV-2 infection that was confirmed by a positive polymerase chain test reaction result between March 1, 2020, and September 3, 2021, who were then propensity score matched to COVID-19-naive people during the same period. Participants with a history of VTE who used antithrombotic drugs (1 year before index dates) or tested positive in hospital were excluded. EXPOSURES: First infection with SARS-CoV-2, age, sex, ethnicity, socioeconomic status, obesity, vaccination status, and inherited thrombophilia. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite VTE, including deep vein thrombosis or pulmonary embolism, which occurred 30 days after the infection. Hazard ratios (HRs) with 95% CIs were calculated using cause-specific Cox models. RESULTS: In 18 818 outpatients with COVID-19 (10 580 women [56.2%]; mean [SD] age, 64.3 [8.0] years) and 93 179 matched uninfected participants (52 177 women [56.0%]; mean [SD] age, 64.3 [7.9] years), the infection was associated with an increased risk of VTE in 30 days (incidence rate of 50.99 and 2.37 per 1000 person-years for infected and uninfected people, respectively; HR, 21.42; 95% CI, 12.63-36.31). However, risk was substantially attenuated among the fully vaccinated (HR, 5.95; 95% CI, 1.82-19.5; interaction P = .02). In patients with COVID-19, older age, male sex, and obesity were independently associated with higher risk, with adjusted HRs of 1.87 (95% CI, 1.50-2.33) per 10 years, 1.69 (95% CI, 1.30-2.19), and 1.83 (95% CI, 1.28-2.61), respectively. Further, inherited thrombophilia was associated with an HR of 2.05 (95% CI, 1.15-3.66) for post-COVID-19 VTE. CONCLUSIONS AND RELEVANCE: In this population-based cohort study of patients with COVID-19, ambulatory COVID-19 was associated with a substantially increased risk of incident VTE, but this risk was greatly reduced in fully vaccinated people with breakthrough infection. Older age, male sex, and obesity were clinical risk factors for post-COVID-19 VTE; factor V Leiden thrombophilia was additionally associated with double the risk, comparable with the risk of 10-year aging. These findings may reinforce the need for vaccination, inform VTE risk stratification, and call for targeted VTE prophylaxis strategies for unvaccinated outpatients with COVID-19.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsCOVID-19Cohort StudiesFemaleFibrinolytic AgentsHumansMaleMiddle AgedObesityRisk FactorsSARS-CoV-2ThrombophiliaVenous Thromboembolism

Zusammenfassung

The risk of venous thromboembolism (VTE) in ambulatory COVID-19 is controversial. In addition, the association of vaccination with COVID-19-related VTE and relevant clinical and genetic risk factors remain to be elucidated.

Warum dies für die Hirudotherapie relevant ist

Diese populationsbasierte Kohortenstudie unter Verwendung von UK-Biobank-Daten (18.818 ambulante Patienten mit bestätigtem SARS-CoV-2, gematcht mit 93.179 nicht infizierten Teilnehmern) ergab, dass ambulantes COVID-19 mit einem erheblich erhöhten 30-Tage-Risiko für venöse Thromboembolie assoziiert war (HR 21,42, 95% CI 12,63-36,31), wobei das Risiko bei vollständig Geimpften deutlich abgeschwächt und bei höherem Alter, männlichem Geschlecht, Adipositas und erblicher Thrombophilie höher war. Für ASH bildet die Studie den Hintergrund für die Erzählung über die Thromboselast, die dem Interesse am antikoagulatorischen Sekretom des medizinischen Blutegels zugrunde liegt; sie untersucht weder die Blutegeltherapie noch irgendeinen blutegelabgeleiteten Wirkstoff. Als Beobachtungskohorte zeigt sie eine Assoziation, keine Kausalität, stützt sich auf Register-/Krankenakten-Kodierung und Propensity-Score-Matching mit möglicher Restkonfundierung und liefert keinen Beleg, der unmittelbar die Wirksamkeit oder Sicherheit der hirudotherapy betrifft.

Zitation

Clinical and Genetic Risk Factors for Acute Incident Venous Thromboembolism in Ambulatory Patients With COVID-19.

Xie J et al. · JAMA internal medicine, 2022

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.